# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target ...
HC Wainwright & Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $35 price t...
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(...
– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial stra...
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.